Information Provided By:
Fly News Breaks for March 4, 2016
TRIB
Mar 4, 2016 | 08:57 EDT
Stephens analyst Drew Jones said Trinity Biotech remains his favorite idea in the Diagnostics/Life Science Tools space for 2016 in a post-earnings research note. The company second straight quarter of matching consensus earnings expectations has re-established "some much needed credibility" on its execution, according to Jones, looks for an acceleration in organic growth this year. The analyst keeps an Overweight rating and $22 price target on Trinity shares.
News For TRIB From the Last 2 Days
There are no results for your query TRIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.